AlgoraeOS
algoraepharma.com
5.5 Club score Visit algoraepharma.com
What the maker publishes
- Benchmarking
- The company says AOS2 outperformed representative state-of-the-art models in published benchmarks. source
- Closed-loop design
- Discovery and pre-clinical development data continuously feed back to strengthen the platform's predictive capability. source
- Current candidates
- The site identifies AI-116 and AI-168 as priority licensing candidates. source
- Data inputs
- The platform connects pre-clinical, clinical, chemical and biological data to generate drug-combination candidates. source
- Dose-response models
- AlgoraeOS models dose-response surfaces using Bliss, Loewe, HSA and ZIP. source
- Headquarters
- Melbourne, Victoria, Australia source
- Headquarters
- Algorae lists its address in Melbourne, Victoria, Australia. source
- Independent validation
- Independent wet-lab validation at Peter MacCallum Cancer Centre tested 21 drug-drug targets across four cancer cell lines, generating approximately 10,000 data points. source
- Intellectual property
- Algorae states that the platform's intellectual property is 100% owned by the company. source
- Licensing and co-development
- Validated candidates are available for out-licensing and co-development with pharmaceutical and biotech partners. source
- Prediction scale
- The platform has generated 500,000 drug-cell line predictions across 3,000+ drugs and 170 cancer cell lines. source
- Purpose
- AlgoraeOS is an AI-powered drug discovery platform that generates drug-combination candidates for licensing and co-development. source
- Research infrastructure
- The UNSW Data Science Hub provides data analysis tools and access to high-performance computing infrastructure for the collaboration. source
- Research partners
- Named research partners are UNSW AI Institute, CSIRO/Data61 and Peter MacCallum Cancer Centre. source
- Training data
- AlgoraeOS was trained on more than 5.5 million unique inhibition records, approximately 11 million with augmentation. source
Checked against the maker's pages on 14 Nov 2026.